Perbandingan Atherogenic Index Of Plasma Dan Profil Lipid Pada Diabetes Melitus Tipe 2 Dan Non-Diabetes

Endang Susilowati; Erna Susanti

doi:10.33474/ejbst.v12i1.661

Authors

Endang Susilowati Program Studi D3 Farmasi, Poltekkes Putra Indonesia Malang, Malang 65123, Jawa Timur, Indonesia
Erna Susanti Program Studi D3 Anafarma, Poltekkes Putra Indonesia Malang, Malang 65123, Jawa Timur, Indonesia

DOI:

https://doi.org/10.33474/ejbst.v12i1.661

Keywords:

Atherogenic Index of Plasma, diabetes melitus tipe 2, profil lipid, risiko kardiovaskular

Abstract

Atherogenic dyslipidemia is a common metabolic abnormality associated with type 2 diabetes mellitus (T2DM). The Atherogenic Index of Plasma (AIP), calculated as the logarithm of the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio, has been proposed as a more comprehensive indicator of atherosclerotic risk than conventional lipid parameters. This study aimed to compare lipid profiles and AIP values between patients with T2DM and non-diabetic individuals in the general population of Malang City, Indonesia. This analytical observational study employed a cross-sectional design involving 77 participants, including 30 patients with T2DM and 47 non-diabetic individuals. The analyzed variables included serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and AIP, which was calculated using the formula log₁₀(TG/HDL-C). Comparisons between groups were performed using the independent-samples t-test, with statistical significance defined as p < 0.05. Patients with T2DM had significantly higher levels of total cholesterol (208.40 ± 43.78 vs. 187.98 ± 40.81 mg/dL; p = 0.045), LDL-C (127.14 ± 32.35 vs. 105.09 ± 29.02 mg/dL; p = 0.004), triglycerides (226.30 ± 138.60 vs. 124.30 ± 59.47 mg/dL; p < 0.001), and AIP (0.73 ± 0.27 vs. 0.44 ± 0.22; p < 0.001) than non-diabetic individuals. Although HDL-C levels were lower in the T2DM group (37.81 ± 8.95 vs. 42.05 ± 9.89 mg/dL), the difference was not statistically significant (p = 0.056). Patients with T2DM exhibited a more atherogenic lipid profile and significantly higher AIP values than non-diabetic individuals. These findings support the potential use of AIP as a complementary biomarker to conventional lipid profile assessment for identifying individuals at increased risk of atherosclerosis and cardiovascular disease among patients with T2DM.

References

N. Marx et al., “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes,” Eur. Heart J., vol. 44, no. 39, pp. 4043–4140, 2023, doi: 10.1093/eurheartj/ehad192.

N. A. Elsayed et al., “8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023,” Diabetes Care, vol. 46, no. January, pp. S128–S139, 2023, doi: 10.2337/dc23-S008.

B. A. Ference, I. Graham, L. Tokgozoglu, and A. L. Catapano, “Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series,” J. Am. Coll. Cardiol., vol. 72, no. 10, pp. 1141–1156, 2018, doi: 10.1016/j.jacc.2018.06.046.

S. Kalra and N. Raizada, “Dyslipidemia in diabetes,” Indian Heart J., vol. 76, pp. S80–S82, 2024, doi: 10.1016/j.ihj.2023.11.002.

M. Dobiášová, “Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: Theoretical and practical implications,” Clin. Chem., vol. 50, no. 7, pp. 1113–1115, 2004, doi: 10.1373/clinchem.2004.033175.

L. M. Andraschko, G. Gazi, D. C. Leucuta, S. L. Popa, B. A. Chis, and A. Ismaiel, “Atherogenic Index of Plasma in Metabolic Syndrome—A Systematic Review and Meta-Analysis,” Med., vol. 61, no. 4, pp. 1–12, 2025, doi: 10.3390/medicina61040611.

L. Fu et al., “Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Cardiovasc. Diabetol., vol. 20, no. 1, pp. 1–11, 2021, doi: 10.1186/s12933-021-01393-5.

S. H. Kim et al., “Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study,” Cardiovasc. Diabetol., vol. 21, no. 1, pp. 1–11, 2022, doi: 10.1186/s12933-022-01522-8.

L. Fu, Y. Zhou, J. Sun, Z. Zhu, Z. Xing, S. Zhou, Y. Wang, and S. Tai, “Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Cardiovascular Diabetology, vol. 20, art. no. 201, 2021, doi: 10.1186/s12933-021-01393-5.

N. H. Oktarina, L. B. Kurniawan, and Nurahmi, “An Atherogenic Index of Plasma in Type 2 Diabetes Mellitus with and without Coronary Artery Disease,” Indones. J. Clin. Pathol. Med. Lab., vol. 31, no. 2, pp. 185–190, 2025, doi: 10.24293/ijcpml.v31i2.2280.

S. Kalra and N. Raizada, “Dyslipidemia in diabetes,” Indian Heart J., vol. 76, no. S1, pp. S80–S82, 2024, doi: 10.1016/j.ihj.2023.11.002.

M. Dobiášová, “Atherogenic impact of lecithin-cholesterol acyltransferase and its relation to cholesterol esterification rate in HDL (FERHDL) and AIP [log(TG/HDL-C)] biomarkers: The butterfly effect?,” Physiol. Res., vol. 66, no. 2, pp. 193–203, 2017, doi: 10.33549/physiolres.933621.

R. Assempoor et al., “Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies,” Cardiovasc. Diabetol., vol. 24, no. 1, 2025, doi: 10.1186/s12933-025-02582-2.

Y. Zhang, G. Chen, and Y. Jing, “Correlation between the atherogenic index of plasma and risk of diabetic retinopathy,” Front. Med., vol. 12, no. May, pp. 1–8, 2025, doi: 10.3389/fmed.2025.1565414.

N. P. S. S. Prabandari, I. A. P. Wirawati, and N. N. Mahartini, “Relationship between Atherogenic Index of Plasma with HbAlc Levels in Type 2 Diabetes Mellitus Patients,” 2021. doi: 10.24293/ijcpml.v28i1.1743.

L. Ismail, H. Materwala, and J. Al Kaabi, “Association of risk factors with type 2 diabetes: A systematic review,” Comput. Struct. Biotechnol. J., vol. 19, pp. 1759–1785, 2021, doi: 10.1016/j.csbj.2021.03.003.

S. C. Thambiah and L. C. Lai, “Diabetic dyslipidaemia,” Pract. Lab. Med., vol. 26, no. May, p. e00248, 2021, doi: 10.1016/j.plabm.2021.e00248.

Y. Y. Zhang, R. Cao, and Q. Wan, “Association between the plasma atherogenic index and type 2 diabetes in Chinese population: prospective cohort study based on 4C study,” Front. Endocrinol. (Lausanne)., vol. 16, no. April, pp. 1–9, 2025, doi: 10.3389/fendo.2025.1571602.

H. Hidaka et al., “Characterization of triglyceride rich lipoproteins with very light density by ultracentrifugation and agarose gel electrophoresis using triglyceride- and cholesterol-staining,” Ann. Clin. Lab. Sci., vol. 33, no. 2, pp. 167–178, 2003.

Y. Shen et al., “Diabetic dyslipidemia impairs coronary collateral formation: An update,” Front. Cardiovasc. Med., vol. 9, no. August, pp. 1–11, 2022, doi: 10.3389/fcvm.2022.956086.

J. Wu, Q. Zhou, Z. Wei, J. Wei, and M. Cui, “Atherogenic Index of Plasma and Coronary Artery Disease in the Adult Population: A Meta-Analysis,” Frontiers in Cardiovascular Medicine, vol. 8, 817441, 2021, doi: 10.3389/fcvm.2021.817441

B. Yin, Z. Wu, Y. Xia, S. Xiao, L. Chen, and Y. Li, “Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study,” Cardiovasc. Diabetol., vol. 22, no. 1, pp. 1–12, 2023, doi: 10.1186/s12933-023-01886-5.

S. Karimpour Reyhan et al., “Atherogenic Index of Plasma (AIP): The Most Accurate Indicator of Overweight and Obesity Among Lipid Indices in Type 2 Diabetes—Findings From a Cross-Sectional Study,” Endocrinol. Diabetes Metab., vol. 7, no. 6, pp. 1–8, 2024, doi: 10.1002/edm2.70007.

Z. L. Wang et al., “Strong association between atherogenic index of plasma and obesity in college students,” BMC Endocr. Disord., vol. 25, no. 1, 2025, doi: 10.1186/s12902-024-01807-x.